Related Experiment Video
Updated: Feb 14, 2026

Application of Flow Vermimetry for Quantification and Analysis of the Caenorhabditis elegans Gut Microbiome
Published on: March 31, 2023
Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a
William Fusco1, Flavio De Maio2, Serena Porcari3
1Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
None:
Background: Untargeted microbiome modulation has achieved conflicting results in post-infectious irritable bowel syndrome (PI-IBS). Methods: In a case-control study of PI-IBS patients, cases received targeted microbial modulation informed by microbiome profiling, while controls were managed by standard therapy. Treatment response was defined as a decrease in IBS-symptom severity scale (IBS-SSS) ≥50 points. Results: All thirteen cases (100%) and 11/20 controls (55%) experienced treatment response (p < 0.0001). The mean IBS-SSS score after treatments was 163 in cases and 231 in controls (p = 0.01). Conclusions: Based on our preliminary results, therapeutic microbiome modulation might be a promising strategy for PI-IBS. Further studies are needed to clarify its role.
Related Concept Videos
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome III: Medical and Nursing Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Pilot and Numeric Relaying
The Stanford Prison Experiment

